Autonomix Medical, Inc.

Clinical/early-stage biotech — clinical-stage neural-sensing device, funded.

Strengths

• Liquidity — current ratio 4.5 (68th)

Risks

• Pre-revenue, deep losses — per metrics
• Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
• Binary clinical & funding risk — per 10-K

Notable findings

• Cash burnNegative free cash flow (-12.3M)
• Material weakness• risks associated with our identification of material weaknesses in our control over financial reporting; • our use of net proceeds received by us from any subsequent private placement or publi
• Buying back stockNet buyback — share count -62%/yr over 2y